Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (NCT05269394)

🧪 Interventions in This Study

• E2814 (DRUG)
• Lecanemab (DRUG)
• Matching Placebo (E2814) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (36 Sites)

Showing the first 25 of 36 sites.

• University of Alabama in Birmingham — Birmingham, Alabama
• University of California San Diego Medical Center — La Jolla, California
• USC Keck School of Medicine — Los Angeles, California
• Yale University School of Medicine — New Haven, Connecticut
• Emory University — Atlanta, Georgia
• Advocate Lutheran General Hospital — Park Ridge, Illinois
• Indiana University School of Medicine — Indianapolis, Indiana
• Washington University in St. Louis — St Louis, Missouri
• University of Pittsburgh — Pittsburgh, Pennsylvania
• Butler Hospital — Providence, Rhode Island
• Kerwin Research Center, — Dallas, Texas
• University of Washington — Seattle, Washington
• Instituto de Investigaciones Neurologicas Raul Carrea, FLENI — Ciudad Autonoma de Buenos Aire,
• Neuroscience Research Australia — Randwick, New South Wales
• Alzheimer's Research Australia — Melbourne, Victoria
• Hospital das Clínicas da Faculdade de Medicina da USP — São Paulo,
• Sunnybrook Health Sciences Centre — Toronto, Ontario
• McGill Center for Studies in Aging — Verdun, Quebec
• CHU de Quebec - Hôpital de l' Enfant Jésus — Québec,
• Grupo de Neurociencias Sede de la Universidad de Antioquia — Medellín,
• CHU de Toulouse - Hôpital Purpan — Toulouse, Haute Garonne
• Hopital Roger Salengro - CHU Lille — Lille, Nord
• Groupe Hospitalier Pitie-Salpetriere — Paris, Paris
• Hopital Neurologique Pierre Wertheimer — Bron, Rhone
• CHU de Rouen - Hôpital Charles Nicolle — Rouen, Seine Maritime

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Alzheimers Disease

• Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease — Atlantis, Florida
• Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 — Birmingham, Alabama
• A Post Authorization Registry Study of Participants Treated With LEQEMBI — Vancouver, British Columbia
• A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Phoenix, Arizona
• A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — Birmingham, Alabama

Explore by condition: All Alzheimers Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.